1. Atrasentan reduces albuminuria in diabetic apoE KO mice.
Atrasentan reduces albuminuria in diabetic apoE KO mice. A: Changes in urinary albumin-to-creatinine ratios (ACRs) from baseline to 4 weeks after treatment, indicated by percentage change from baseline. Data are shown as mean ± SD (n = 19–23). *P < B and C: Glomerular morphology in diabetic apoE KO mice is not affected by treatment with atrasentan (DM + A) for 4 weeks compared with untreated diabetic apoE KO mice (DM). After treatment, no change in blood glucose concentrations (D) or systolic blood pressure (SBP) (n = 8) (E) is observed. Scale bars: 20 μm. ApoE, apoE KO mice.
Margien G.S. Boels et al. Diabetes 2016;65:
©2016 by American Diabetes Association